“…The current pharmacological chaperoning hypothesis suggests that these changes only require concentrations of nicotine to be high enough to interact with the specific subtype in the endoplasmic reticulum, meaning surface activation is not required (8,18) Other nAChR ligands, including drugs that have been evaluated as smoking cessation agents, have also been shown to up-regulate nAChRs. These drugs include the partial agonists cytisine (19) and varenicline (20) as well as the antagonist mecamylamine (21). Although nicotine exposure increases the assembly of the high sensitivity receptor, (␣4) 2 (2) 3 (16,22), cytisine has been shown to alter the stoichiometry of ␣42 with a preference for the low sensitivity receptor, (␣4) 3 (2) 2 , potentially due to the existence of an additional binding site for cytisine at the ␣-␣ interface (23,24).…”